bitop AG and Activaero collaborate on clinical study of inhalable Ectoin-solution
bitop AG and Activaero GmbH announced the start of a clinical study on bitop AG’s medical device Ectoin® inhalation solution using Activaero’s controlled breathing technology, the AKITA² inhalation system. Ectoin® inhalation solution is based on Ectoin®, an extremolyte, a natural substance developed by bitop AG and currently available in topical skin creams and nasal sprays for the treatment of dry and irritated tissue.
The present clinical study is a single-center dose-finding, safety and feasibility study involving patients with mild bronchial asthma in Germany. Ectoin® inhalation solution has already shown marked therapeutic efficacy in animal models of allergen induced asthma and the purpose of the study is to investigate the safety and tolerability of Ectoin® inhalation solution in the treatment of asthma.
According to the company, the AKITA²® inhalation system allows for homogeneous drug deposition of aerosolized Ectoine® within the periphery of the lungs in a consistent and reproducible manner. The system also has a smart card technology meaning that data on compliance and dosing can be recorded automatically for each patient.
Other news from the department business & finance
